para-azidoethoxyphenylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: para-azidoethoxyphenylalanine
• 英文别名: p-azidoethoxyphenylalanine；H-L-Tyr(2-azidoethyl)-OH；(2S)-2-amino-3-[4-(2-azidoethoxy)phenyl]propanoic acid
• 化学式: C₁₁H₁₄N₄O₃
• 分子量: 250.257
• InChiKey: AFRGRMSRGXONSC-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl (S)-3-(4-(2-bromoethoxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate 在 sodium azide 、 三氟乙酸 、 lithium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 para-azidoethoxyphenylalanine
  参考文献：
  名称：

  非天然氨基酸的合成和掺入以探测和优化蛋白质生物偶联。

  摘要：

  由于非天然氨基酸（UAA）具有一定程度的生物正交性和特异性，因此它们在生物结合中的应用是理想的。为了阐明制备具有UAA的生物共轭物的最佳条件，我们合成了9个带有可变亚甲基系链（2-4）和叠氮化物，炔烃或卤化物官能团的UAA。然后使用混杂的氨酰基-tRNA合成酶将所有9个UAA掺入绿色荧光蛋白（GFP）中。然后通过与荧光团或衍生化的树脂反应，分析不同的生物共轭物的最佳系链长度。有趣的是，发现最佳的系链长度取决于反应的类型。总的来说，这些发现提供了对各种参数的更好的理解，这些参数可以被优化以有效地制备生物缀合物。

  DOI：

  10.1021/acs.bioconjchem.5b00424

文献信息

• [EN] ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-AGONISTES DE TLR, PROCÉDÉS ET UTILISATIONS DE CEUX-CI
  申请人：AMBRX INC

  公开号：WO2022040596A1

  公开（公告）日：2022-02-24

  Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.

  本文披露了TLR-激动剂化合物、抗体-TLR激动剂结合物、制药组合物以及使用这些化合物或结合物作为治疗癌症等疾病或病症的治疗剂的方法。
• COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES
  申请人：Ambrx, Inc.

  公开号：EP3923991A1

  公开（公告）日：2021-12-22
• [EN] COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES<br/>[FR] CONTENANT DE COMPOSITIONS, PROCÉDÉS ET UTILISATIONS DE CONJUGUÉS ANTICORPS-AGONISTES TLR
  申请人：AMBRX INC

  公开号：WO2020168017A1

  公开（公告）日：2020-08-20

  Disclosed herein are Trastuzumab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzumab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post- translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzumab- linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use.
• [EN] INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS POLYPEPTIDIQUES D'INTERLEUKINE-2 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMBRX INC

  公开号：WO2021183832A1

  公开（公告）日：2021-09-16

  The present invention provides compositions and methods comprising interleukin-2 (IL-2) polypeptide conjugates. Also described are IL-2 conjugates for the treatment of diseases or conditions including cancer,
• [EN] ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-HER2 ET LEURS UTILISATIONS
  申请人：[en]AMBRX, INC.

  公开号：WO2022212899A1

  公开（公告）日：2022-10-06

  Disclosed herein are antibody-drug conjugates (ADCs) whose antibodies include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The ADCs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid ADCs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such ADCs. Typically, the modified ADCs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid ADCs and modified non-natural amino acid ADCs, including therapeutic, diagnostic, and other biotechnology use.